Viral vector manufacturing and transfection efficiency in the iCELLis® Bioreactor System
Cell & Gene Therapy Insights 2020; 6(10), 1573–1585
Listen to the full podcast:
Listen to each individual question and answer:
Click here to access the Guide for DNA Transfection in iCELLis® 500 and iCELLis 500+ Bioreactors for Large Scale Gene Therapy Vector Manufacturing
Dr Rachel Legmann is currently serving as the technical lead at Pall’s gene therapy business unit. In her role she is supporting global customers and building high level networks, Rachel is supporting various internal cross-functional activities including due diligence and new product development. Rachel has more than 20 years of experience in the field of scalable manufacturing of therapeutic products, viral vector and proteins for gene therapy, oncolytic and biologics. She completed her PhD in Food Engineering and Biotechnology at the Technion-Israel Institute of Technology, Israel. Rachel joined Pall in 2014 as the senior lab manager established the US accelerator process development services lab and led the upstream, downstream, analytics and project manager teams for serving multiple customers bringing various viral vector products into the clinical. Prior to joining Pall, Rachel held several scientific and leadership roles at Microbiology & Molecular Genetics department at Harvard Medical School, SBH Sciences, Seahorse Biosciences, and Goodwin Biotechnology.
François Collard, PhD, is supporting the Pall Accelerator Process Development Service, and R&D, as a Bio-Process Knowledge Manager. He holds a PhD in bio-chemistry from the de Duve Institute & University of Louvain (Belgium) and performed a post-doc at the Case Western Reserve University (Cleveland, OH) in the field of structural biology and enzyme catalysis. He started his career at Pall as a scientific lead of various process development projects, such as viral vaccines, gene therapy and exosomes.
Alengo Nyamay’antu is a Scientific Communication Specialist at Polyplus-transfection® SA, the leading biotechnology company that supports Gene and Cell therapy, biologics manufacturing and life science research with innovative nucleic acid transfection solutions. Alengo completed her MSc in structural and functional biochemistry at the University of Lyon and went on to specialise in protein biochemistry at the University of Manchester. She then continued to develop and widen her scientific and communication skills by joining the Max Planck Institute for Biomedicine as a postdoctoral researcher.